No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Cimzia is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is a tumor necrosis factor (TNF) blocker, which works by blocking the action of TNF, a protein that plays a role in inflammation. Cimzia is administered by subcutaneous injection and is available in both prefilled syringes and autoinjectors.
The Cimzia market is highly competitive, with several major players offering similar products. These include AbbVie, Amgen, Janssen, and Pfizer. Other companies in the market include UCB, Merck, and Bristol-Myers Squibb. These companies offer a range of products, including biosimilars, which are similar to Cimzia but are not identical.
The Cimzia market is expected to continue to grow in the coming years, driven by increasing demand for treatments for immune disorders. The market is also expected to benefit from the development of new products and technologies, such as biosimilars. Show Less Read more
